<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109665</url>
  </required_header>
  <id_info>
    <org_study_id>B16/66</org_study_id>
    <nct_id>NCT03109665</nct_id>
  </id_info>
  <brief_title>Glaucoma Within Northern Ireland Cohort for the Longitudinal Study of Ageing</brief_title>
  <acronym>GwNICOLA</acronym>
  <official_title>Glaucoma Within Northern Ireland Cohort for the Longitudinal Study of Ageing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University, Belfast</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is the leading cause of irreversible blindness worldwide. It is caused by damage to&#xD;
      the optic nerve between the back of the eye and the brain leading to progressive blindness.&#xD;
      The cause is poorly understood but ageing, increased intraocular pressure (IOP) and genetics&#xD;
      are all likely to play a role. There is no cure for glaucoma but treatments are available&#xD;
      which slow progression. Because vision cannot be restored once lost, early detection,&#xD;
      monitoring and early treatment are all essential to preserve visual function.&#xD;
&#xD;
      The condition is diagnosed using a combination of the appearance of the optic nerve on&#xD;
      clinical examination or photograph and visual field testing (perimetry). Measurement of IOP&#xD;
      and measurement of the thickness of the retinal layers at the back of the eye complement&#xD;
      diagnostic decisions.&#xD;
&#xD;
      The Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) study does not&#xD;
      include perimetry in the series of tests carried out on all participants but does include&#xD;
      photography of the optic nerve, measurement of IOP and measurement of retinal thickness.&#xD;
      Therefore we propose to invite back participants of the NICOLA study who have abnormal optic&#xD;
      discs and high eye pressure to return for perimetry to confirm a diagnosis of glaucoma.&#xD;
      Calling back participants for perimetry is essential to make the diagnosis not only for&#xD;
      estimating prevalence but also for identifying participant's ill-health.&#xD;
&#xD;
      The primary aim of this study is to quantify the number of participants in the NICOLA study&#xD;
      who have glaucoma and report its risk factors. This will allow an estimate of the number of&#xD;
      people in the whole of NI with glaucoma. We will also perform a series of novel tests using&#xD;
      state-of-the-art technologies to assess if they are better than current tests at diagnosing&#xD;
      glaucoma. This may enable better informed decisions about policy decisions in eyecare.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose and design: This study will answer the following research questions:&#xD;
&#xD;
        1. What is the prevalence of glaucoma within the NICOLA cohort and which systemic and&#xD;
           socioeconomic factors influence its prevalence?&#xD;
&#xD;
        2. What is the diagnostic accuracy (sensitivity and specificity) of Retinal Nerve Fibre&#xD;
           Layer (RNFL) thickness measurements in the diagnosis of glaucoma?&#xD;
&#xD;
        3. What is the diagnostic accuracy (sensitivity and specificity) of macular thickness&#xD;
           analysis in the diagnosis of glaucoma?&#xD;
&#xD;
        4. What is the agreement between intraocular pressure measurement by Ocular Response&#xD;
           Analyser (ORA) and Goldmann tonometry?&#xD;
&#xD;
        5. What is the correlation between structural (circumpapillary RNFL or macular Ganglion&#xD;
           Cell Complex thickness) or functional measurements (retinal oximetry or perimetry) and&#xD;
           Optical Coherence Tomography angiography parameters (% vessel density and vessel&#xD;
           calibre) in the assessment of glaucoma?&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Glaucoma in Northern Ireland</measure>
    <time_frame>1 day [2 hours]</time_frame>
    <description>Prevalence of Glaucoma in Northern Ireland</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic Accuracy of Spectral Domain OCT</measure>
    <time_frame>1 day [2 hours]</time_frame>
    <description>Diagnostic Accuracy of Spectral Domain OCT</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">129</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Glaucoma within NICOLA</arm_group_label>
    <description>NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SD-OCT Angiography</intervention_name>
    <description>SD-OCT Angiography</description>
    <arm_group_label>Glaucoma within NICOLA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SD-OCT</intervention_name>
    <description>SD-OCT</description>
    <arm_group_label>Glaucoma within NICOLA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NICOLA Study - Random sample of 8500 non-institutionalised adults &gt;50 years from Northern&#xD;
        Ireland GwNICOLA participants derived from NICOLA Study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants of the NICOLA study who gave permission to be contacted by the NICOLA&#xD;
             study team in future and&#xD;
&#xD;
          2. Vertical cup to disc ratio ≥0.7 and/or inter-eye asymmetry ≥0.2 or neuroretinal rim&#xD;
             ≤0.1 or intraocular pressure ≥25 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non English speakers or&#xD;
&#xD;
          2. Participants of the NICOLA study who did not give permission to be contacted by the&#xD;
             NICOLA study team in future&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Augusto Azuara-Blanco, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University Belfast</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northern Ireland Clinical Research Facility</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University, Belfast</investigator_affiliation>
    <investigator_full_name>Professor Augusto Azuara-Blanco</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

